We serve Chemical Name:4-Methylpyrimidine-2-carboxylic acid CAS:933738-87-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Methylpyrimidine-2-carboxylic acid
CAS.NO:933738-87-5
Synonyms:4-methylpyrimidine-2-carboxylic acid
Molecular Formula:C6H6N2O2
Molecular Weight:138.12400
HS Code:2933599090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:362.8ºC at 760 mmHg
Density:1.319g/cm3
Index of Refraction:1.566
PSA:63.08000
Exact Mass:138.04300
LogP:0.48320
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-methylpyrimidine-2-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-methylpyrimidine-2-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-methylpyrimidine-2-carboxylic acid Use and application,4-methylpyrimidine-2-carboxylic acid technical grade,usp/ep/jp grade.
Related News: In its message to the public, the FDA said that a person should consider being retested if they used Innova’s diagnostic within the past two weeks. 4-Methylpyrimidine-2-carboxylic acid manufacturer Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships. 4-Methylpyrimidine-2-carboxylic acid supplier In its message to the public, the FDA said that a person should consider being retested if they used Innova’s diagnostic within the past two weeks. 4-Methylpyrimidine-2-carboxylic acid vendor In its message to the public, the FDA said that a person should consider being retested if they used Innova’s diagnostic within the past two weeks. 4-Methylpyrimidine-2-carboxylic acid factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.
